QTRX Earnings Prediction
The chart below shows how QTRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, QTRX sees a +1.24% change in stock price 10 days leading up to the earnings, and a +4.34% change 10 days following the report. On the earnings day itself, the stock moves by +0.22%. This data can give you a slight idea of what to expect for the next quarter's release.
QTRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
2.18M
-93.09%
-93.92%
Gross Margin
63.05%
2.50%
12.05%
Operating Margin
-42.00%
7.83%
28.05%
Net Margin
-33.07%
18.40%
41.81%
EPS
-0.30
-30.43%
36.36%
No Data Available
QTRX Earnings Analysis
Quanterix Corp Corporation (QTRX.O) Earnings Conference Call
Positive
Consistent Revenue Growth: Quanterix delivered its seventh consecutive quarter of double-digit revenue growth, achieving $35.2 million in revenue, an 11% increase year-over-year.
Accelerator Lab Revenue Growth: The Accelerator lab revenue grew by 22% in the quarter, indicating strong demand for testing services and custom assay development.
Gross Margin Improvement: Non-GAAP gross margin improved to 57.7%, up 300 basis points from the previous year, driven by higher pricing and improved operational efficiency.
Cash Usage Decline: Cash usage declined by 31% to $4.4 million in the fourth quarter, reflecting better cash management and operational performance.
Revenue and Recurring Growth: Over the past two years, Quanterix achieved a revenue CAGR of 14% and increased recurring revenues from 65% to 80%.
New Assays Launch: The company launched 20 new assays in 2024, including 13 in neurology, expanding its product offerings in key therapeutic areas.
Market Expansion Strategy: Quanterix is expanding into the immunology and oncology markets through the Simoa ONE platform and the proposed acquisition of Akoya Biosciences, which is expected to enhance growth.
Market Expansion Potential: The acquisition of Akoya is projected to expand Quanterix's addressable market significantly, from $1 billion to $5 billion in research and from $10 billion to $15 billion in diagnostics.
Positive Free Cash Flow: The company expects to generate positive free cash flow by 2026, one year earlier than if it remained standalone, indicating a strong path to profitability.
Strategic R&D Investments: Quanterix's strategic investments in R&D and diagnostics are expected to yield strong returns and support future growth.
Negative
Earnings Miss Report: Quanterix Corporation missed earnings expectations with a reported EPS of $-0.3, compared to expectations of $-0.27.
Consumable Revenue Stagnation: Consumable revenue was flat at $17.4 million compared to the previous year, indicating a stagnation in this segment as customers transition to Advantage PLUS assays.
Instrument Revenue Decline: Instrument revenue decreased by 7% year-over-year, highlighting a decline in sales despite a sequential increase of 29%.
Revenue Decline Forecast: The company expects a revenue decline of 10% to 15% in the first quarter of 2025, driven by challenges in the US academic market and timing of accelerator projects.
2025 Revenue Growth Outlook: Guidance for 2025 indicates only 2% to 6% revenue growth, which is significantly lower than previous growth rates, reflecting market volatility and reduced demand from academic customers.
Increased Cash Usage: Cash usage for the year increased by $15 million compared to the prior year, indicating higher operational costs despite a reduction in cash burn in the fourth quarter.
Declining Adjusted EBITDA: Adjusted EBITDA was negative $23.6 million in 2024, worsening from negative $19 million in 2023, suggesting ongoing financial challenges despite strategic investments.
QTRX FAQs
How does QTRX typically perform around its earnings report dates?
Is Quanterix Corp (QTRX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
QTRX Earning Call Sentiment
Quanterix Corporation (NASDAQ:QTRX) Q4 2024 Earnings Call Transcript
QTRX.O
2.38%Positive
The earnings call presents a mixed picture. Financial performance shows growth, but concerns arise from delayed pharma contracts, increased expenses, and lack of shareholder returns. The Q&A reveals uncertainties in the academic market and unclear revenue contributions, slightly dampening sentiment. However, reaffirmed guidance, strong demand for Alzheimer's products, and strategic growth initiatives balance these concerns. Without market cap data, the overall sentiment remains neutral, reflecting a balanced outlook with potential for both positive and negative short-term movements.
